GLUE · Monte Rosa Therapeutics, Inc. · Executive Compensation
$10.27
-0.23 (-2.19%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.00B
Shares
85.31M
Volume · Oct 5
1.75M
Avg daily vol (3M)
1.3M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Markus Warmuth | Chief Executive Officer | $5,032,728 |
| Filip Janku | M.D., Ph.D. Chief Medical Officer | $1,941,781 |
| Phil Nickson | Chief Business and Legal Officer | $1,941,781 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Markus Warmuth | Chief Executive Officer | $2,440,811 |
| Phil Nickson | Chief Business and Legal Officer | $1,287,628 |
| Filip Janku | M.D., Ph.D. Chief Medical Officer | $1,257,869 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Matthew Bowen | Corporate Controller and Principal Accounting Officer | Appointed | 2026-02-10 |
| Edmund Dunn | SVP, Corporate Controller and Principal Accounting Officer | Retired | 2026-02-10 |
| Eric A. Hughes, M.D., Ph.D. | Class III director | Appointed | 2024-12-13 |
| Jennifer Champoux | Chief Operating Officer | Appointed | 2024-05-30 |
| Owen Wallace | Chief Scientific Officer | Resigned | 2024-05-02 |
| Anthony M. Manning, Ph.D. | Class II director | Appointed | 2023-07-26 |
| Jan Skvarka, Ph.D., MBA | Class I director | Appointed | 2023-03-23 |